India's first dengue vaccine, Qdenga, requires careful rollout and affordability for at-risk populations.
The CDSCO's approval of Qdenga, India's first dengue vaccine, is a significant step, following its licensing in over 40 countries and WHO prequalification. However, the editorial cautions against complacency. Concerns include the vaccine's varying protection against different serotypes (especially DENV-3 and DENV-4), the two-dose regimen's logistical challenges for mobile populations, and potential 'negative efficacy' issues in seronegative children from the TIDES trial. The article stresses the need for government negotiation for lower pricing to ensure affordability and uptake among high-risk populations, particularly in dense urban slums where conventional vector control is difficult.
Key Points
- India has approved Qdenga, its first dengue vaccine, following international licensing and WHO prequalification.
- The vaccine's efficacy varies across the four dengue serotypes, with concerns about protection against DENV-3 and DENV-4.
- Logistical challenges exist for administering the two-dose regimen, especially for highly mobile populations.
- Potential risks, such as 'negative efficacy' in seronegative children, need careful monitoring during rollout.
- The government must negotiate for an affordable price to ensure equitable access for at-risk populations, particularly in urban slums.
Exam Facts
- CDSCO (Central Drugs Standard Control Organisation) approved the Qdenga dengue vaccine.
- Qdenga is developed by Japan-based Takeda.
- There are four antigenically distinct dengue serotypes (DENV-1, DENV-2, DENV-3, DENV-4).
- The TIDES trial raised concerns about 'negative efficacy' against DENV-3 among seronegative children.
- The Aedes mosquitoes spread dengue.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.